Youcare Pharmaceutical Group Co. Ltd. Class I innovative drug Bai Rui Extract Granules launches Phase I clinical study
On March 16, the kick-off meeting for the Phase I clinical research project of Youcare Pharmaceutical Group Co. Ltd. Bairui Extract Granules was held grandly at Peking University Third Hospital. This drug is used to treat respiratory tract infections in adults and children characterized by acute upper respiratory tract infections, with a special focus on the clinical drug gap in children. It is a national Class I innovative traditional Chinese medicine developed by Youcare Pharmaceutical Group Co. Ltd. in response to the national strategy for revitalizing traditional Chinese medicine.
Directors of the Drug Clinical Trial Institution of Peking University Third Hospital Li Haiyan and Director Wang Xiaohong together with their research teams, Chairman of Youcare Pharmaceutical Group Co. Ltd. Mr. Yu Weishi together with the core team of the sponsor and the research team of CRO Beijing Yuelaixin Pharmaceutical Technology Co., Ltd. gathered at the scene to witness this milestone moment.
Top platform escorts and builds a solid foundation for clinical research
As the top drug clinical trial institution in China, Peking University Third Hospital has a professional research team, a complete test platform and rich experience in phase I clinical research, providing comprehensive technical support and quality assurance for this study.
Director Li Haiyan said that Chairman Yu's admirable responsibility for adhering to the original intention of innovation and deepening the research and development of new drugs. The research team will allocate optimal resources to promote the phase I clinical research process as quickly as possible, with high standards and high quality, to help the innovative achievements of traditional Chinese medicine be launched as soon as possible.
Keeping integrity and innovating to support the development of traditional Chinese medicine
As a traditional Chinese medicinal material, basil is included in authoritative works such as the "Chinese Pharmacopoeia". It is known as a "plant antibiotic" because of its outstanding anti-infective effect. Yuekang Pharmaceutical's marketed product Bairui Capsule has excellent performance in treating upper respiratory tract infections and has been widely praised by authoritative experts such as Academician Han Demin of the Chinese Academy of Engineering.
Yu Weishi, Chairman of Youcare Pharmaceutical Group Co. Ltd., said that on this basis, Youcare Pharmaceutical Group Co. Ltd. actively responded to the country’s major strategic deployment of revitalizing and developing traditional Chinese medicine, adopted new technologies to achieve innovative breakthroughs, and developed Bai Rui Extract Granules, a Class I innovative traditional Chinese medicine, and is committed to protecting the health of the people with traditional Chinese medicine innovation.
Focus on drug demand gap, preclinical data is eye-catching
Children and the elderly have a high incidence of acute upper respiratory tract infections, and are prone to complications such as bronchitis and pneumonia. However, there are still many limitations in their clinical treatment. Bairui extract granules take into account the medication needs of adults and children, accurately focus on clinical medication gaps, and are expected to provide safer and more effective innovative traditional Chinese medicine options for patients in the future.
Preclinical studies have shown that the drug exhibits good animal efficacy and safety. Pharmacodynamic studies have confirmed that it has significant therapeutic effects on pneumonia in mice caused by influenza virus, parainfluenza virus, and respiratory syncytial virus infection, and it also has pharmacological effects such as anti-inflammatory, analgesic, and cough relieving; safety pharmacology and toxicology studies have confirmed that it has good safety, laying a solid foundation for the development of clinical trials.
In the future, Youcare Pharmaceutical Group Co. Ltd. will continue to take national strategies as the guide and clinical needs as the core, and deepen the modern research and development and innovation upgrading of traditional Chinese medicine, so that more high-quality innovative traditional Chinese medicines can benefit the majority of patients, and contribute to ensuring the health of the whole people and promoting the high-quality development of the traditional Chinese medicine industry.
Feedback | Beijing Yuelaixin Pharmaceutical Technology Co., Ltd.
Editor | Li Mengting
Photography | Luan Chuanqi Ren Gaoyuan
Review | Liu Dingchao
Statement:
This press release is intended to convey the company's major news and promote the communication and exchange of medical information. It is not for advertising purposes.
Our company does not recommend any drugs and/or indications.
The information involved in this article is for reference only and cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If you want to know more about the diagnosis and treatment of specific diseases, please follow the advice or guidance of your doctor or other medical health professionals.
↓ Learn more about Yuekang news ↓ Chairman Yu Weishi was invited to watch the military parade ceremony Ginkgo leaf extract injection | Yuekang Huoxin Pills (concentrated pills) Moving towards the new Quality wins the future Top 100 Pharmaceutical Industry | National Civilized Unit Chairman Yu Weishi talked about "innovation" with Dr. Peking University Chairman Yu Weishi's trip to France